This research shows Lariocidin's significant antimicrobial activity against multidrug-resistant pathogens, suggesting its potential as an alternative antibiotic.
Antimicrobial resistance (AMR) is a major global health crisis, necessitating the discovery of novel antibiotics. In a recent study, Lariocidin, a newly identified lasso peptide, was isolated from Paenibacillus species and demonstrated significant antimicrobial activity against multidrug-resistant (MDR) pathogens. Unlike conventional antibiotics, Lariocidin functions by targeting bacterial ribosomes through a distinct mechanism, preventing resistance development. In vitro and in vivo studies confirmed its efficacy, non-toxicity, and stability. This research highlights Lariocidin’s potential as a next-generation antibiotic, though further pharmacokinetic studies are required to ensure its clinical applicability.
No takes yet. Share an insight, caveat, or question.
Ashish Pandey (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: